Back to top
more

DBV Technologies (DBVT)

(Delayed Data from NSDQ)

$0.69 USD

0.69
40,904

0.00 (-0.22%)

Updated Apr 25, 2024 03:58 PM ET

After-Market: $0.70 +0.01 (1.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DBVT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

DBV Technologies S.A. [DBVT]

Reports for Purchase

Showing records 1 - 20 ( 47 total )

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 1

03/08/2024

Company Report

Pages: 7

Viaskin Closer to Sticking-Supplemental Safety Trials on Near-Term Horizon; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 2

02/21/2024

Daily Note

Pages: 4

Injectable Food Allergy Label Extension - An Apples to Oranges Comparison to Viaskin;

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 3

11/13/2023

Daily Note

Pages: 4

Positive EPITOPE OLE Data in Toddlers; COMFORT Toddlers Trial De-Risking; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 4

11/01/2023

Company Report

Pages: 7

Viaskin Patch Execution With FDA Protocol Feedback - Looking to 1Q24 Enrollment; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 5

08/01/2023

Company Report

Pages: 7

Next Steps for Viaskin Peanut-Type C Meeting Safety Studies That Can Stick; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 6

05/09/2023

Company Report

Pages: 7

Considerations on Defined Paths Forward for Viaskin Patch; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 7

03/03/2023

Company Report

Pages: 7

Next Near-Term Steps For Viaskin and Looking to EPITOPE Success; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 8

11/04/2022

Company Report

Pages: 7

Engagement With FDA Can Get VITESSE Trial to Stick; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 9

09/08/2022

Daily Note

Pages: 4

Phase 3 VITESSE Trial Initiation-Positioning of Viaskin Peanut for Success

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 10

08/02/2022

Company Report

Pages: 7

Phase 3 VITESSE Trial Clarity to Define Near-Term Viaskin Advancement

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 11

06/08/2022

Daily Note

Pages: 4

Phase 3 EPITOPE Trial Affirms Viaskin Benefit in Toddlers; Next Sights on Modified Patch

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 12

05/03/2022

Company Report

Pages: 7

Viaskin Peanut Type C Meeting—A Viable Path to 2Q22 Agency Alignment

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 13

03/04/2022

Company Report

Pages: 77

Finalizing a Pivotal Viaskin Protocol That Can Stick; Expecting 2022 Clarity

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 14

12/21/2021

Company Report

Pages: 7

Viaskin Modified Patch Clarity, Albeit in Form of New Pivotal Trial; PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 15

10/27/2021

Company Report

Pages: 7

Viaskin Patch Regulatory Update Shifts to Stepwise Advancement

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for DBVT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 17

08/03/2021

Company Report

Pages: 7

We Maintain Lead Viaskin Program Can Find Adhesion; Reit Buy and $14 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 18

05/04/2021

Company Report

Pages: 7

A Viaskin Peanut Strategy on the Horizon That Can Stick - Our Thoughts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 19

03/12/2021

Company Report

Pages: 7

Elucidated Next Steps As Viaskin Modification is Front and Center

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: DBV Technologies S.A.

Industry: Medical - Biomedical and Genetics

Record: 20

01/15/2021

Daily Note

Pages: 3

An Opportunity That Could Stick - FDA Clarity Outlines Next Steps for Viaskin

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party